BARK’s $11 Poll Is Half Its Old Split-Adjusted Bid

No-trade screen — Reject. At Friday’s $8.16 regular-session close, GNK’s newly floated $11 cash price looks like 34.8% upside. But it is only a non-binding interest poll, not a tender offer; it is also half the $22 per-share equivalent of GNK’s January proposal, which BARK’s special committee rejected before the 1-for-20 reverse split. BARK’s operating outlook has since weakened enough that $22 is not a current fair-value anchor. The fresh disagreement is worth tracking, but neither the base case nor the downside clears the Desk’s long hurdle.

Publication time: 2026-09-28 13:44 Asia/Singapore · Scope: U.S. market; long opportunities only · Selected screen: BARK, Inc. (BARK), not a selected trade Reference observation: $8.16 regular-session close on 2026-09-25, 16:00 EDT; 113,856 shares reported traded. The quote is context, not an executable entry. [1]

Opportunity Ranking

Rank	Candidate	Direction	Mispricing	Evidence Freshness	Catalyst Window	Positioning	10/5 Status	Tradeability	Main Rejection Risk
1	BARK	Long screen	$11 poll is 34.8% above the close but half the old $22 split-adjusted proposal; no formal offer exists.	GNK release Sep. 25; latest issuer operating guide Aug. 6; prior board rejection Mar. 20.	Shareholder-interest deadline Oct. 9; any formal tender is unannounced.	No current tender tally or direct flow data; low recent share volume is not a positioning measure.	Reject: 0% reference base move; 38.1% modeled adverse stress.	Common stock only; market-quality gates absent.	No offer, partial/pro-rated acceptance, or standalone deterioration.
2	Delek US (`DK`)	Long screen	A $400M 0% convertible due 2031 was priced at an $85.31 conversion price, 27.5% above the Sep. 24 close; this is a capital-structure event, not demonstrated per-share value creation.	Pricing announced Sep. 25.	Proceeds use and subsequent debt/cash changes require filing reconciliation.	Conversion terms are disclosed; current hedge, holder, and flow positioning is not.	Reject: no sourced 10% base case or bounded adverse case from the new note terms alone.	NYSE common; full live execution evidence not reviewed.	Proceeds may only refinance or shift claims; future conversion dilutes. [7]
3	Lumen (`LUMN`)	Long screen	NYSE-to-Nasdaq transfer may change investor optics, but the announced action is a venue change; no parallel operating or financing event was disclosed.	Company release and 8-K Sep. 25.	Expected Oct. 5 close / Oct. 6 Nasdaq open, subject to conditions.	No event-specific positioning evidence found.	Reject: no operating or cash-flow disagreement supports a 10% base case.	NYSE common; no execution audit.	Listing transfer produces no cash or operating change. [8]

Selected opportunity: None qualifies. BARK ranks first for information value because a fresh potential-bidder statement reopens a previously closed transaction path on materially lower split-adjusted terms; it is not the best executable opportunity.

Why this one now: GNK introduced an Oct. 9 information deadline, creating a cheap, observable test of whether it will progress beyond solicitation. Its own release says it is still deciding whether enough interest exists to justify a formal offer, and says neither shareholders nor GNK are committed. [2]

What should surprise the reader: The nominal $11 price is not an improved version of the January bid. BARK’s 1-for-20 split turns that earlier $1.10 proposal into $22 on today’s share basis. The 50% nominal reset matters, but so does the deterioration in BARK’s subsequently reported revenue outlook; the old rejected price is history, not intrinsic value.

Why This Is the Best Information Event, Not a Trade

The strongest bullish argument is straightforward: $11 is 34.8% above $8.16, BARK reported no debt and $16.1 million of cash at June 30, and management reiterated a $7–$10 million FY27 adjusted EBITDA outlook. A buyer seeking influence could also make a later formal offer more credible than an isolated rumor. [3]

The stronger underwriting objection is that there is no offer to accept, no committed buyer capital disclosed, no minimum or maximum tender size, no acceptance mechanics, and no indication tally. Even if GNK does proceed, its intended purchase may be partial, so $11 is not a guaranteed exit for every share. The new $11 reference is below the same group’s earlier rejected $22 split-adjusted proposal, while BARK now guides to FY27 revenue of $325–$340 million versus FY26’s $394.8 million. The bid reset may be responding to real operating deterioration rather than creating a clean bargain. [2][3][4]

Why This Can Move More Than 5% Soon

The transaction branch can move the quote sharply: a formal offer near $11 would imply a large premium to the reference close. The opposite branch is also large: GNK can stop after the Oct. 9 poll, or announce a limited tender whose terms and participation do not support $11 for all holders. Separately, BARK’s next operating update can confirm or refute whether higher adjusted EBITDA can coexist with falling revenue and a smaller direct-to-consumer subscriber base. The event creates volatility, not positive asymmetry.

10/5 Asymmetry Gate

Test	Reference-only result	Desk threshold	Finding
Highest-probability base case	$8.16; 0.0%	At least +10%	Fails
Credible adverse stress	$5.05; -38.1%	No worse than -5%	Fails; not a proven floor
Base reward / adverse risk	0.00:1	At least 2:1	Fails
Probability-weighted gross return	-6.2% before costs	Positive after costs	Fails before costs
Measurement basis	Sep. 25 close, reference only	Verified executable entry	Not met

Classification: Reject / no trade. These numbers do not show that the close is a fair value or that $5.05 is a support level. They show that even a deliberately explicit scenario map cannot establish the required base return or downside bound. Entry remains null and execution remains blocked.

The Setup

GNK’s Sep. 25 statement describes a possible cash tender at $11 and asks holders to submit non-binding indications by Oct. 9. It expressly says the deadline is only for gathering interest, is not a tender-offer expiration date, and that no tender offer has commenced. GNK may use the responses to decide whether to proceed and, if so, to determine size, structure, and terms. [2]

This is a new evidence boundary versus the Desk’s May 27 screen, which treated the January proposals as stale and the then-open special-committee process as unresolved. The issuer closed that process on Mar. 20, rejecting GNK’s proposal as inadequate. The Sep. 25 announcement is materially new because GNK has returned with a lower split-adjusted price and an explicit interest-gathering step. It does not revive the January proposal or create a formal offer. [4][5]

The Market Price

BARK closed at $8.16 on Sep. 25, up 0.74% from $8.10 the prior session; the vendor reports 113,856 shares traded that day versus 31,234 on Sep. 24. The Sep. 25 session high was $8.84 and the close was $8.16. This is a small one-day net change around GNK’s release, not proof that the market accepted or rejected the proposal. Bid/ask, spread, depth, venue quality, volume quality, and practical exit capacity were not verified. [1]

The June 30 10-Q reports 9,925,385 common shares issued and outstanding and $16.09 million cash, with no debt. A market-data provider reports 9.037 million shares and roughly $74.3 million market capitalization for Sep. 25. Those denominators do not reconcile; I do not use the provider market-cap field to calculate enterprise value or crowding. [3][6]

The Mispricing

Fact: the $11 figure is a potential tender price under evaluation, not a formal offer. Fact: GNK proposed $1.10 per share in January; BARK later effected a 1-for-20 reverse split, making the simple split-adjusted equivalent $22. Fact: BARK’s committee rejected the January proposal as inadequate and ended its review in March. [2][4][5]

Inference: the market may be pricing a meaningful probability that GNK’s renewed interest becomes a tender or activism path. But the premium headline suppresses two important conditions: any tender size or proration is unknown, and the buyer’s proposed price is half its prior split-adjusted reference. The market may instead be correctly discounting the chance that a deteriorating standalone business and non-binding interest poll produce no realizable $11 exit.

The operating counterweight is material. BARK’s Aug. 6 release guided Q2 FY27 revenue to $83–$85 million versus $107 million a year earlier, attributing the decline primarily to the smaller DTC subscriber base after a deliberate marketing pullback. Full-year FY27 revenue guidance was $325–$340 million versus FY26 revenue of $394.8 million, while adjusted EBITDA guidance rose to $7–$10 million from $0.2 million. Net income for Q1 included $7.4 million of tariff refunds allocable to FY26; the issuer also says adjusted EBITDA excludes items such as stock compensation and capital expenditures. [3]

The Positioning

The offer-interest process could reveal willingness to tender, but GNK has not published a tally. A low-volume tape can magnify price moves and impede exits; it does not establish short crowding, forced selling, or buyer demand. Current beneficial ownership changes, short-interest settlement date, borrow fee and recall terms, options positioning, dealer exposure, and fund flows were not established in the primary material reviewed. Positioning is therefore unknown, not bullish.

The Catalyst

Step	State and timing	Observable test	Failure or delay path
Shareholder-interest poll	Open; responses due Oct. 9, 2026.	GNK publishes a decision or files formal tender documents.	GNK says participation is insufficient or provides no update. No duty to proceed.
Formal tender	Not commenced; date, terms, size, financing, and conditions unknown.	SEC-filed Schedule TO, offer-to-purchase, and related documents.	No offer, changed price/size, conditions not met, or withdrawal.
BARK operating proof	FY27 guide issued Aug. 6; next report date not verified in this run.	Revenue, subscribers, gross margin, cash flow, and share count versus guidance.	Revenue declines while non-GAAP EBITDA fails to convert into cash.

The cheapest falsification test is whether GNK makes a formal, SEC-filed offer after the Oct. 9 interest window. An indication sent by an individual holder would not establish the aggregate tally and is not needed for this analysis. A formal filing would still leave financing, conditions, proration, and completion to verify.

The Payoff

Price Target and Probability Map

The 90-day horizon runs through Dec. 27, 2026. Scenarios are mutually exclusive, subjective estimates rather than observed frequencies. “Top” assumes a formal $11 tender is launched and closes within the horizon and that a holder’s shares are accepted; the public announcement does not promise full acceptance. “Base” assumes no binding transaction and uses the last close only as a flat reference. “Bottom” is a standalone stress calculation, not a liquidation value or floor.

Scenario	Probability	Target / Level	Return / Payoff	Horizon	Conditions	Evidence Quality
Top Case	15%	$11.00	+34.8%	Through Dec. 27, 2026	Formal offer at the stated price launches and closes; shares are accepted.	Low: no offer, size, funding, or acceptance terms.
Base Case	55%	$8.16	0.0%	Through Dec. 27, 2026	No binding offer; last regular close held as a neutral reference, not a forecast.	Low: subjective no-deal weighting.
Bottom Case	30%	$5.05	-38.1%	Through Dec. 27, 2026	Interest poll does not produce a transaction and standalone expectations weaken; stress multiple applied to guidance.	Low: valuation multiple is an assumption.
Invalidation	n/a	No formal offer after GNK ends its evaluation, or operating results materially miss the FY27 guide.	Remove the catalyst or standalone-recovery rationale; do not convert this to an automatic exit price.	At the relevant filing or update	Official bidder/issuer evidence.	Medium

Probability-weighted expected value: $7.65 per share, or -6.2% versus $8.16, before costs. Calculation: 0.15 × $11 + 0.55 × $8.16 + 0.30 × $5.05 = $7.653.
Current market level and timestamp: $8.16, Sep. 25, 2026 regular-session close, 16:00 EDT.
Primary instrument: none; this is a no-trade screen.
10/5 favorable base move: 0.0%.
10/5 credible adverse move: 38.1% reference-only stress; not a proven bound.
10/5 measurement basis: reference-only; executable entry is unavailable.
10/5 status: Reject.
Confidence: Low. The tender is uncommenced and the downside multiple and scenario weights are judgmental.

The downside stress is calculated as (4.0 × $8.5 million FY27 adjusted EBITDA midpoint + $16.09 million June 30 cash) ÷ 9.925 million June 30 shares = $5.05. It uses a 4.0× multiple solely as a stress assumption, adds reported cash, assumes no debt, and uses the last-filed basic denominator. It does not establish fair value, and it does not resolve lease obligations, cash consumed since June, stock compensation, capex, or subsequent share-count changes. The market-data vendor’s lower share count is not substituted because its reconciliation to the issuer’s filed figure is unknown. [3][6]

Sensitivity: At a 6.0× rather than 4.0× stress multiple, the same bridge gives about $6.76 per share; with the same 15%/55%/30% scenario weights, expected value is about $8.17 before costs—effectively flat. Keeping the base weight at 55% and shifting probability between the top and bottom cases, the $5.05 stress map needs about a 23.5% top-case probability merely to lift expected value to $8.16. Neither sensitivity makes the base case +10% or caps credible downside at 5%; modest costs make the near-flat optimistic sensitivity negative.

The Kill Shot

The strongest counterargument is that a debt-free company with $16.1 million of reported cash, improving adjusted EBITDA guidance, and a motivated former bidder can be worth more than a weak price implies; GNK’s renewed public interest may also force attention from other shareholders or potential buyers. [2][3]

The load-bearing assumption behind any long is that GNK’s polling step converts into funded, acceptably sized terms before the standalone business deteriorates further. That assumption has no primary evidence yet. Even if directionally right, the trade can lose through no offer, proration, a lower formal price, a delay beyond the horizon, or earnings/cash conversion below guidance. The old $22 equivalent is not a downside floor or a current buyer commitment.

What Could Go Wrong

GNK ends its review without filing tender documents; no one owes shareholders a progress update.
A future tender is partial or prorated, leaving some shares exposed to standalone value.
BARK misses its FY27 adjusted EBITDA outlook, revenue contracts faster, or cash declines through seasonal working capital and repurchases.
The $16.09 million cash balance is stale, the filed share count changes, or adjusted EBITDA fails to translate into cash after stock compensation and investment needs.
Thin trading produces a gap, halt, wider spread, or exit price materially worse than any scenario mark.

What Would Prove This Wrong

The no-trade conclusion would need reassessment—not automatic reversal—if GNK files a funded tender with a defined minimum/maximum size, clear acceptance and proration terms, and price materially above the standalone stress; BARK’s board response and legal conditions are also required. Separately, a reported quarter showing revenue stabilization, positive operating cash conversion, current cash, and a reconciled share count could raise the standalone base. A fresh regular-session market-quality audit would still be necessary before any executable entry.

Risk Audit

Decision-quality distinction: GNK’s announcement is real; a $11 tender is not. The operating improvement in adjusted EBITDA is issuer guidance, not audited future performance or cash. The $5.05 case is a valuation sensitivity, not an observed market floor. The central uncertainty is factual (whether a binding offer arrives) and valuation-related (what standalone economics merit); no positioning data closes either gap.

Residual risks include tender withdrawal or non-launch, operating losses, cash burn, litigation or governance conflict, a materially changed denominator, trading halts, gaps, slippage, carrying costs, and poor exit liquidity. No stop price can prevent a discontinuous loss. No personalized recommendation is made.

Best Trade Strategy

No trade. Do not enter on the headline premium. Reassess only after formal tender materials and a current BARK operating/capital update; verify the exact terms, all-shares versus partial acceptance, board position, funding, and current denominator. Before any order, verify a fresh regular-session quote, bid/ask, spread, depth, venue and volume quality, and realistic exit capacity. No options, leverage, margin, market orders, or price-floor logic are supported.

Sources

BARK historical prices, including Sep. 25 regular close and volume, checked for this run.
GNK Holdings’ Sep. 25 announcement seeking non-binding interest in a potential $11 tender, sourced to GNK via PRNewswire.
BARK Q1 FY2027 results and outlook, filed Aug. 6, 2026.
BARK special committee’s Mar. 20 decision not to pursue GNK’s proposal.
BARK 1-for-20 reverse split, effective Apr. 1, 2026; BARK’s earlier disclosure of GNK’s $1.10 proposal.
BARK Q1 FY2027 Form 10-Q, including June 30 cash and share count; provider Sep. 25 share-count context.
Delek US Sep. 25 convertible-note pricing release, reproducing the company’s Business Wire announcement.
Lumen Sep. 25 SEC Form 8-K on Nasdaq listing transfer.

Research Quality Scorecard

Criterion	Score	Evidence-based reason
Market disagreement	4/5	Headline tender premium conflicts with non-binding status and half-old split-adjusted terms.
Evidence base	4/5	Fresh bidder release, issuer filing, board decision, reverse-split filing, and market quote.
Positioning and flows	2/5	No tender tally or current direct crowding data.
Catalyst path	3/5	Oct. 9 interest deadline is observable, but it creates no obligation to proceed.
Payoff architecture	3/5	Arithmetic is transparent; standalone multiple and subjective event weights are weak.
Invalidation discipline	4/5	Formal-filing, operating, and execution tests are explicit.
Differentiated insight	4/5	Split-adjusted comparison reveals the nominal $11 headline is a 50% lower reference.
Client value	4/5	Clarifies what the event is, what it is not, and the exact evidence needed next.
Total	28/40	No-trade Reject; the score cannot override the failed 10/5 gate.

Bottom Line

GNK has reopened contact with BARK holders, not the tender itself. The $11 figure offers a large headline premium to Friday’s close but is half the prior bid on a split-adjusted basis, while BARK’s revenue guide has since reset lower. With no binding offer, no accepted-share terms, a flat highest-probability reference case, and a plausible downside well beyond 5%, the Desk rejects a long. The useful next evidence is a formal filing after the Oct. 9 poll and a fresh operating/cash bridge—not the poll headline.

AI Illustration Prompt

Create an editorial illustration for The Mispricing Desk: a quiet, forensic tabletop with two BARK transaction documents, one labeled “JANUARY $1.10 → $22 POST-SPLIT” and one labeled “SEPTEMBER $11? NON-BINDING.” Place a small 1:20 split ruler between them and a sealed envelope marked “Oct. 9 indications” that is visibly unopened. In the background, a subdued dog-toy package and a cash-flow statement hint at the standalone business without using a real company logo. Graphite, warm paper, restrained amber, institutional financial-journal mood, precise typography, no celebratory takeover imagery. Add a subtle readable “The Mispricing Desk” watermark at lower right.